Related Experiment Videos
A lyoluminescent tissue-equivalent dosemeter for pion therapy beams
Physics in Medicine and Biology
|May 1, 1983
Summary
Lyoluminescent glucose dosimetry accurately measures pion beam depth dose distribution, showing a Bragg peak ratio similar to ionization chambers. This offers advantages over TLD-700 for clinical pion therapy.
Area of Science:
- Medical Physics
- Radiation Dosimetry
- Particle Therapy
Background:
- Pion therapy requires accurate dose distribution measurements.
- Current methods like LiF (TLD-700) show deviations in pion dosimetry.
- Glucose offers potential as a tissue-equivalent dosimeter.
Purpose of the Study:
- To evaluate glucose lyoluminescence for measuring pion beam depth dose distribution.
- To compare glucose lyoluminescence with ionization chamber and LiF (TLD-700) responses.
- To assess glucose's suitability as a dosemeter in clinical pion therapy.
Main Methods:
- Irradiating glucose with 170 MeV/c pi-mesons.
- Measuring emitted light from dissolved glucose in luminol solution.
- Comparing lyoluminescence profiles with TE ionization chamber measurements.
- Assessing LiF (TLD-700) thermoluminescence response to pions.
Main Results:
- Glucose lyoluminescence intensity is proportional to pion beam depth dose distribution.
- Lyoluminescence closely matches ionization chamber profiles with a 3:1 Bragg peak to plateau ratio.
- LiF (TLD-700) showed significant deviation from this ratio.
- Accurate dose measurements (0.5-30 Gy) with +/- 5% accuracy and 3-5% reproducibility were achieved.
Conclusions:
- Glucose lyoluminescence is a viable method for measuring pion depth dose distribution.
- Glucose exhibits superior tissue equivalence and non-toxicity compared to LiF for pion dosimetry.
- Glucose lyoluminescence offers significant advantages for in vivo measurements in clinical pion therapy.